Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, October 28, 2010 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori; “Astellas”) and its US affiliate Astellas US LLC (headquarters: Deerfield, IL;...
Tokyo, October 28, 2010 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that it submitted a market authorization application for...
Tokyo, October, 25, 2010—Astellas Pharma Inc. (“Astellas”; President and CEO: Masafumi Nogimori) announced that the “Flying Star Fund,” a social contribution fund run by employees, has...
Tokyo and Akita, Japan, September 30, 2010 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) and UMN Pharma Inc. (“UMN Pharma”; headquarters:...
Zeria Pharmaceutical Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President and CEO: Sachiaki Ibe; “Zeria”) and Astellas Pharma Inc. (Headquarters: Chuo-ku, Tokyo; President and CEO: Masafumi...
Tokyo, September 29, 2010 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced that it submitted a market authorization application for...
Osaka and Tokyo, Japan, September 10, 2010 - Ono Pharmaceutical Co., Ltd. (“Ono”; headquarters: Osaka; President and Representative Director: Gyo Sagara) and Astellas Pharma Inc....
Tokyo, Japan, September 8, 2010 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced the donation of three high-standard ambulances to local...
Astellas Pharma Inc. and its US subsidiary, Astellas Pharma US, Inc. ("Astellas") and Teva Pharmaceutical USA, Inc. ("Teva") announced today that the three companies have reached an agreement to...
Japan, May 12, 2010 – Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori, hereinafter called “the Company”) today announced that at the meeting of the Board of...
Japan, April 28, 2010 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori; “Astellas”) today announced that its US subsidiary, Astellas Pharma US,...
Japan, 1 March 2010 - Astellas Pharma Inc. (“Astellas”; Headquarters: Tokyo, President & CEO: Masafumi Nogimori) today announced that its subsidiary Astellas Pharma US, Inc. (Headquarters:...
Japan, February 26, 2010 - Astellas Pharma Inc. (“Astellas” Headquarters: Chuo-ku, Tokyo; President & CEO: Masafumi Nogimori) announced today the withdrawal of the application for approval of...
Tokyo, Japan, February 24, 2010 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that it has entered into a license,...
Japan, January 19, 2010 - Astellas Pharma Inc. ("Astellas";Headquarters: Tokyo, President & CEO: Masafumi Nogimori) today announced that it will make a donation of 5 million yen to the Japanese...
Tokyo, Japan, January 12, 2010 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) and AstraZeneca K.K. (headquarters: Tokyo; President and CEO:...
Japan, December 22, 2009 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced that it submitted an application for market authorization for...
Japan, December 14, 2009 – Astellas Pharma Inc. (Headquarters: Tokyo, President and CEO: Masafumi Nogimori, hereinafter called the “the Company”) announced that it completed acquisition of...
Tokyo, Japan, December 11, 2009 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) and AstraZeneca K.K. (headquarters: Tokyo; President and CEO:...
Tokyo, Japan, November 26, 2009 – Pfizer Japan Inc. (“Pfizer”) and Astellas Pharma Inc. (“Astellas”) today announced that combination drug of hypertension treatment and...
Tokyo, Japan, November 26, 2009 – Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that its North American affiliate, Astellas Pharma US, Inc....
Tokyo, Japan, November 5, 2009 -Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that it has decided to transfer the functions of...
Japan, November 5, 2009 – Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori, hereinafter called the “the Company”) announced that at the meeting of the Board of...
Japan, October 26, 2009 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that it has decided to terminate the development of...
Tokyo, Japan, October 16, 2009 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that it was granted approval for “myasthenia...
Tokyo, Japan, October 16, 2009 - AstraZeneca K.K. (headquarters: Tokyo; President and CEO: Masuhiro Kato) today announced that it received a Japanese manufacturing and marketing approval for...
Tokyo, Japan, October 7, 2009 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that Astellas and Boehringer Ingelheim Pharmaceuticals, Inc. (a US...
Tokyo, Japan, September 25, 2009 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori; “Astellas”) today announced that Boehringer Ingelheim Pharmaceuticals, Inc. (“
Tokyo, Japan, September 24, 2009 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori; “Astellas”) and its US affiliate Astellas Pharma US, Inc. (headquarters:...
Tokyo, Japan, September 2, 2009- Astellas Pharma Inc. (“Astellas”, Headquarters: Chuo-ku, Tokyo; President & CEO: Masafumi Nogimori) announced today that it has established a fund laboratory...
Tokyo, Japan, August 26, 2009 – Pfizer Japan Inc. (“Pfizer”) and Astellas Pharma Inc. (“Astellas”) today announced that the companies have reached a co-promotion agreement for a...
Tokyo, Japan, August 21, 2009 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori; “Astellas”) today announced that the groundbreaking ceremony for Fermentation...
Tokyo, Japan, August 21, 2009 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that it has decided to reorganize its drug...
As stated in the press release issued on August 11, 2009, Astellas Pharma US, Inc. (“Astellas Pharma US”; headquarters: Deerfield, IL), North American affiliate of Astellas Pharma Inc....
Tokyo, Japan, August 11, 2009- Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that its North American affiliate, Astellas Pharma...
Tokyo, Japan, August 4, 2009 - AstraZeneca K.K., the Japanese subsidiary of AstraZeneca PLC and Astellas Pharma Inc. (“Astellas”) today announced that AstraZeneca AB (“AstraZeneca”) and...
Tokyo, Japan, July 20, 2009, Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that it has established Astellas Farma Brasil...
Tokyo, Japan, July 13, 2009 - Astellas Pharma Inc. (“Astellas”; Headquarters: Tokyo; President and CEO: Masafumi Nogimori)today announced that the FAMOUS (Famotidine for the Prevention of Peptic U
Tokyo, Japan, July 7, 2009 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that it was granted approval for moderately/severely...
Tokyo, Japan, July 1, 2009 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori; “Astellas”) today announced that Boehringer Ingelheim Pharmaceuticals, Inc....
Tokyo, Japan, July 1, 2009 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori)today announced that Maxygen, Inc. (“Maxygen”; headquarters:...
Nippon Boehringer Ingelheim Co., Ltd. (Headquarters: Shinagawa-ku, Tokyo: Chairman & President: Dr. Thomas Heil) and Astellas Pharma Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Masafumi...